Shoulder Innovations Announces FDA Clearance of New InSet™ Stemless Humeral Implant

Shoulder Innovations Inc., (SI), a leading innovator in the development of shoulder replacement systems, announces the FDA Clearance of their latest component of the InSet™ Total Shoulder System, the InSet™ Stemless Humeral System.

The InSet™Stemless implant is the latest addition to the innovative and integrated InSet™ system, which already includes the successful InSet™ Glenoid, Humeral Short Stem and Reverse components.

The new Stemless device is a component of the first truly integrated shoulder system in the world, combining stemless and stemmed, in both anatomic and reverse configurations in the same platform.

[mks_pullquote align=”right” width=”400″ size=”24″ bg_color=”#1e73be” txt_color=”#ffffff”]Rob Ball, CEO of Shoulder Innovations said, “This most recent product clearance from the FDA is a key component to our multi-product strategy to provide the simplest and most elegant solutions on the market for shoulder surgery.  We have packaged the equivalent of six innovative products in this simple instrumentation set.  We refer to this is as The Power of One, and are proud to bring unmatched efficiency to the market.”[/mks_pullquote]

This platform makes use of the identical instruments and surgical techniques as the existing InSet™ Humeral Short stem, allowing flexibility for intraoperative decision-making with no cost in time or any additional instruments or bone preparation required.

Previously surgeons had to choose—stem or stemless—for each surgical case without the option to easily change from one to the other.  This concise configuration, the first of its kind, is also expected to help reduce O.R. time and reflect savings related to cleaning and sterilization processing costs.

The unique design for the humeral preparation allows for the least amount of bone removal while the implant’s curved fin design maximizes axial and rotational fixation surface area.

Rob Ball, CEO of Shoulder Innovations said, “This most recent product clearance from the FDA is a key component to our multi-product strategy to provide the simplest and most elegant solutions on the market for shoulder surgery.  We have packaged the equivalent of six innovative products in this simple instrumentation set.  We refer to this is as The Power of One, and are proud to bring unmatched efficiency to the market.”

Matt Ahearn, Chief Operations Officer for Shoulder Innovations said, “The addition of the Stemless system expands the clinical options available to our surgeon partners, with the same anatomic surgical technique and no incremental instrumentation. This is extremely exciting for Shoulder Innovations, as we have significant demand from clinicians who want to pair a Stemless implant with our InSet™ Glenoid technology.

David Blue, Chief Commercial Officer at Shoulder Innovations said, “The Stemless implant is another transformational addition to the InSet™ Shoulder System, where we continue to transcend shoulder science.”

The InSet™ Stemless device will be available at select U.S. sites in the coming weeks.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version